Rebecca Metzinger, MD
Ophthalmology · New Orleans, LANPI 1073564167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,422 of the $62,700 with a category attached, or 77.2%. 26 manufacturers reported payments, led by Omeros Corporation at 53.9% of the total. Reporting peaked in 2021 at $29,241 and has fallen 96.7% since, to $958 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $522.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$34K
- Rayner Intraocular Lenses Limited$23K
- Alcon$2K
- AbbVie$1K
- Glaukos Corporation$696
- Sun Pharmaceutical Industries Inc.$248
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$48,42277%
- Travel & lodging$8,34913%
- Food & beverage$5,8199%
- Education$800%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 30 | $33,808 |
| Rayner Intraocular Lenses Limited | 19 | $22,589 |
| Alcon | 11 | $2,075 |
| AbbVie(2 entities) | 16 | $1,305 |
| Glaukos Corporation | 11 | $696 |
| Sun Pharmaceutical Industries Inc. | 2 | $248 |
| Harrow Eye, LLC | 3 | $232 |
| Nova Eye, Inc. | 1 | $218 |
| Aerie Pharmaceuticals, Inc. | 2 | $202 |
| Sight Sciences, Inc. | 3 | $190 |
| NEW World Medical,inc. | 2 | $155 |
| Amgen | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Zimmer Biomet | 1 | $123 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $103 |
| Johnson & Johnson Vision Care, Inc. | 1 | $68 |
| Tarsus Pharmaceuticals, Inc. | 2 | $61 |
| Biotissue Holdings Inc. | 3 | $58 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Apellis Pharmaceuticals, Inc. | 1 | $53 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $50 |
| Dompe US, Inc. | 2 | $46 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Merz North America, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,700 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $7,972 |
| LumiganBimatoprost | 16 | $4,368 |
| Prednisolone Acetate | 82 | $3,240 |
| Brimonidine Tartrate | 46 | $462 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $458 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $452 |
| Ketorolac Tromethamine | 16 | $397 |
| Latanoprost | 75 | $385 |
| Dorzolamide Hcl | 17 | $334 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $288 |
| ErythromycinErythromycin Base | 14 | $171 |
| Timolol Maleate | 20 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan | $202 | $7,97213 claims |
| AbbVieLumigan | $1,305 | $4,36816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in New Orleans
- Ze ZhangNew Orleans$44K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Matthew BoltonNew Orleans$5K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.